Patient #:
1
2
3
4
Current Age
50
54
48
38
Sex
M
Race
White
Ethnicity
Hispanic
Non-Hispanic
MSM Status
Yes
Years with HIV
0.5
7.5
1.8
7.9
Age at Dx of MCD
47
46
35
HHV-8 Status at Time of MCD Dx
Positive
Comorbidities
HIV Treatment(s)
1. bictegravir, emtricitabine, & tenofovir (current)
Last CD4+ count before MCD Dx (cells/mm3)
49
85
451
102
Table 1: Demographics and medical history of patients diagnosed with MCD
Patient
MCD Treatment
Length of Remission
rituximab & doxorubicin
5 months
R-EPOCH x6 (rituximab, etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin)
7 years & 5 months (89 months)
Chemo declined
N/A
rituximab x10, gamma globulin x2
2 years & 10 months (34 months)
Table 2: Treatments and length of remission of patients diagnosed with MCD
Studies of HIV/HHV-8+ patients with MCD treated with rituximab
Study
n of patients
Associated treatment
Survival (mos)
Corbellino, et al. [18]
None
14+
Marcelin, et al. [20]
5
4+, 6+, 14+, 1, 1
Newsom-Davis, et al. [22]
4+
Neuville, et al. [21]
etoposide
22+, 32+
Gérard, et al. [17]
24
12+ (n = 22) 1 (n = 1) 4 (n = 1)
Table 3: Studies of HIV/HHV-8 patients with MCD treated with rituximab chemotherapy